Making very early ovarian cancer screening possible

An estimated 1 out of 78 women will get ovarian cancer in their lifetime in the U.S. Over 65% of women are diagnosed with ovarian cancer after the disease has spread and when the 5-year relative survival rate is only ~25%-29%. If there were a test sensitive and specific enough to detect the early stages of ovarian cancer when the disease is still localized in women, then the 5-year relative survival rate could increase to over 90%. Currently, no screening test exists today to detect ovarian cancer early. This post is intended to elevate awareness and conversation around bridging the gap to enable early ovarian cancer detection and to make very early ovarian cancer screening possible.

GenEndeavor’s mission is to shift the paradigm of genetic testing by developing a new generation of technologies to enable early detection and screening of molecular biomarkers. We encourage updates on the latest research efforts and technologies to identify and detect ovarian cancer biomarkers for screening. We also encourage bringing ovarian cancer awareness to high-risk women, their families, and average-risk women in the general population to inform them about the current state of genetic testing and other preventative measures that can be taken. We welcome your feedback.